Wongtim 1995.

Methods	Setting: Thailand, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Intervention period: 8 weeks Masking: double blind Excluded: not stated Withdrawals: stated (none) Baseline characteristics: comparable Jadad score=3
Participants	20 adults: 10M 10F Mean (SD) age: budesonide 33.2(7.5) years, placebo 32.8(8.6) years Inclusion criteria: Mild asthma with presence of coughing or wheezing within the last 3 years 15% or greater improvement in FEV1after inhaled beta2 agonist Exclusion criteria: Use of systemic steroids, ketotifen or disodium cromoglycate within last 3 months
Interventions	BUD: 200 mcg 2 pfs 2xdaily (800 mcg/d) Placebo: 2 pfs 2xdaily Delivery device: Turbuhaler DPI
Outcomes	Methacholine BHR (PC20 FEV1) Daily asthma symptom score Weekly beta2 agonist use Withdrawal due to asthma exacerbation
Notes	No reply from author to clarify details of randomisation method. Methacholine challenge data not log transformed prior to analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear